Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2026-01-19 Major Shareholding Noti…
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2026
Major Shareholding Notification Classification · 1% confidence The document is a regulatory filing from the Swedish Financial Supervisory Authority (Finansinspektionen) regarding a 'flaggningsmeddelande' (flagging notification). It details a change in shareholding (a sale) by Avanza Bank Holding AB in Oncopeptides AB, crossing the 5% threshold. This is a classic major shareholding notification.
2026-01-19 Swedish
Oncopeptides announces Q4 2025 sales and updates cash-flow expectations
Earnings Release Classification · 1% confidence The document is an initial announcement of quarterly financial results (Q4 2025 sales) and updated cash-flow expectations. It provides key highlights and management commentary but explicitly states that the full end-of-year report will be published at a later date (February 19). Therefore, it qualifies as an Earnings Release (ER) rather than a full report. Q4 2025
2026-01-15 English
Oncopeptides offentliggör omsättning för fjärde kvartalet 2025 och uppdaterar förväntningar på kassaflödesmål
Earnings Release Classification · 1% confidence The document is a press release from Oncopeptides AB announcing preliminary revenue figures for Q4 2025 and updating cash flow expectations. It provides key financial highlights (revenue growth, cash flow targets) and mentions that the full year-end report will be published later on February 19. Since this is an initial announcement of financial results (key highlights only) rather than the full comprehensive report, it is classified as an Earnings Release (ER). Q4 2025
2026-01-15 Swedish
Oncopeptides har utsett valberedningen
Regulatory Filings
2025-11-21 Swedish
Oncopeptides announces the Nomination Committee
Regulatory Filings
2025-11-21 English
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 1% confidence The document is titled 'DELÅRSRAPPORT Q3 2025' (Interim Report Q3 2025) for Oncopeptides. It contains comprehensive financial statements, including the income statement, balance sheet, cash flow, and management commentary for the third quarter and the nine-month period ending September 30, 2025. It also includes an auditor's review report. This fits the definition of an Interim/Quarterly Report (IR). Q3 2025
2025-11-05 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.